PROCEPT BioRobotics Stock
Medical device company
About PROCEPT BioRobotics Stock
PROCEPT BioRobotics is a clinical-stage medical device company based in Silicon Valley. The Company has developed a disruptive surgical product for transurethral resection of prostate tissue – The AquaBeam® – and other treatment and diagnostic applications. The AquaBeam is a personalized image-guided tissue removal system, which utilizes proprietary heat-free high-velocity waterjet technology to resect and remove a predetermined volume of tissue with precise and automated incisions conforming to the shape of the prostate.
Investors
Novo Holdings
Perceptive Advisors
Viking Global Investors
Moderna Therapeutics, Impossible Foods, Ginkgo Bioworks, Adaptive Biotechnologies, Druva, Credit Karma, PROCEPT BioRobotics, Apeel Sciences, Birchbox, Roivant Sciences
Funding History
| October 2013 | $6.0M |
|---|---|
| August 2014 | $2.0M |
| July 2015 | $7.7M |
| July 2015 | $42.0M |
| June 2017 | $25.0M |
| February 2018 | $118M |
Management
President, CEO
Dr. Nikolai Aljuri
Press
massdevice - May, 20 2019
massdevice - Mar, 26 2019
businesswire - Mar, 13 2019
nanalyze - Jul, 20 2018
massdevice - May, 21 2018
fiercebiotech - May, 21 2018
massdevice - Feb, 21 2018
massdevice - Dec, 21 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from PROCEPT BioRobotics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
